BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brochot E, Riachi G, Plantier JC, Guillemard C, Vabret A, Mathurin P, Nguyen-Khac E, Duverlie G. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. J Med Virol. 2013;85:1191-1198. [PMID: 23918537 DOI: 10.1002/jmv.23592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561 [PMID: 28469811 DOI: 10.4254/wjh.v9.i11.551] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Kadla SA, Dar MA, Shah NA, Khan BA, Shah AI, Pathania R, Parveen S. Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study. Indian J Pharmacol 2020;52:372-7. [PMID: 33283768 DOI: 10.4103/ijp.IJP_516_18] [Reference Citation Analysis]